Demographic Data and Clinical Presentation of Pediatric Uveitis

April 2, 2025 updated by: Hasnaa Salah Ebrahim Abo Elyuon, Assiut University

Demographic Data and Clinical Presentation of Pediatric Uveitis Patients in Upper Egypt.

To describe and analyze the demographics, Clinical characteristics, etiology, and visual outcomes of pediatric uveitis cases attending the outpatient clinic of Ophthalmology department, Assiut University Hospital.

Study Overview

Status

Not yet recruiting

Conditions

Pediatric Uveitis

Detailed Description

Uveitis is a form of eye inflammation that affects the middle layer of tissue in the eye wall (uvea).

It is the third leading cause of blindness worldwide .Uveitis is more common in adults; however, children comprise 2.2% to 21.6% of patients in various studies.Despite a lower incidence of uveitis in children, the rate of visual loss may be worse than that of adults . The onset of uveitis in children is often insidious and is only discovered during routine screening.The lack of significant symptoms and delayed presentation to an ophthalmologist leads to morbidity and a decrease in visual acuity . The length of time between the diagnosis of uveitis and the referral to a tertiary eye center is strongly correlated with the complications rate and degree of visual impairment.

Uveitis is classified according to the International Uveitis Study Group criteria based on the anatomical location of the inflammation and is categorized as anterior, intermediate, Posterior or panuveitis. It is also described based on clinical onset, duration and course.

Some uveitis syndromes are unique to children, such as juvenile idiopathic arthritis (JIA), Kawasaki syndrome, Familial Juvenile Systemic Granulomatosis and Tubulointerstitial Nephritis-Uveitis syndrome. Other conditions are more prevalent in the pediatric population due to environmental factors such as trematode induced uveitis.

Due to the lack of epidemiological studies on the demographic and Clinical Characteristics of pediatric uveitis in Upper Egypt. This study aims to improve diagnosis, management, and treatment strategies tailored to the population.

Study Type

Observational

Enrollment (Estimated)

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Name: Hasnaa Salah Ebrahim Abo Elyuon, master
Phone Number: +201090793398
Email: Hassnaa.16266153@med.aun.edu.eg

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

Child
Adult

Accepts Healthy Volunteers

Sampling Method

Non-Probability Sample

Study Population

pediatric patients

Description

Inclusion Criteria:

Uveitis patients <18 years old
must be able to participate in the study.

Exclusion Criteria:

Age over 18 years.
Patients with post pentrating ocular trauma.
Patients whose legal guardians are unwilling to participate in the study.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Distribution of uveitis subtypes. Time Frame: Baseline	Baseline
Differences by age, gender, or ethnicity. Time Frame: Baseline	Baseline
Prevalence of systemic associations. Time Frame: Baseline	Baseline
Prevalence of Visual outcomes. Time Frame: Baseline	Baseline
Prevalence of complications rate. Time Frame: Baseline	Baseline

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Assiut University

Investigators

Study Director: Mohamed Sharaf El Din Abd El Rahim, professor, Assiut University
Study Director: Mohmed Gamal Ahmed Saleh, Assistant Professor, Assiut University
Study Director: Eslam Mohamed Mohamed Goda, Lecturer, Assiut University

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

General Publications

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Estimated)

April 1, 2025

Primary Completion (Estimated)

April 1, 2026

Study Completion (Estimated)

May 1, 2026

Study Registration Dates

First Submitted

March 13, 2025

First Submitted That Met QC Criteria

April 2, 2025

First Posted (Actual)

April 9, 2025

Study Record Updates

Last Update Posted (Actual)

April 9, 2025

Last Update Submitted That Met QC Criteria

April 2, 2025

Last Verified

March 1, 2025

More Information

Terms related to this study

Additional Relevant MeSH Terms

Other Study ID Numbers

Pediatric Uveitis

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Studies a U.S. FDA-regulated device product

product manufactured in and exported from the U.S.

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Demographic Data and Clinical Presentation of Pediatric Uveitis